Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 176   

Articles published

BMY 60.61 -0.21 (-0.35%)
price chart
Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce ...
NEW YORK & QUEENSLAND, Australia--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies ...
Company Shares of Bristol-Myers Squibb Company (NYSE:BMY) Drops by -0.75%  Insider Trading Report
Jefferies Group Cuts Bristol-Myers Squibb Price Target to $59.00 (BMY)  Financial Wisdom Works
Piper Jaffray Upgrades Bristol-Myers Squibb, Sees Valuation As Fair
With the meaningful decline in the share price since Bristol-Myers Squibb Co (NYSE: BMY) announced its Q2 earnings, the stock is now trading close to its fair value.
Bristol-Myers Squibb Co (BMY) Stock Update  Bidness ETC
Bristol-Myers Squibb Company Short Interest Update  Money Flow Index
Why Gilead Sciences, Inc. Can Easily Take Over Bristol-Myers Squibb Co
The only recent deal struck by Gilead has been the purchase of a small cancer firm, EpiTherapeutics Aps, earlier this year for $65 million.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) Sees Large Outflow of Money  American Trade Journal
Bristol-Myers Squibb Company (NYSE:BMY) Price Target Update  News Watch International
Piper Jaffray Upgrades Bristol-Myers Squibb Co. (BMY) to Neutral
Piper Jaffray upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Underweight to Neutral with a price target of $61.00 as fair value has been reached.
FDA Pushes Back Decision on Expanded Use of Bristol-Myers Squibb Drug Opdivo
The Food and Drug Administration pushed back the decision date on an expanded use of Bristol-Myers Squibb Co. BMY -0.35 % 's cancer drug Opdivo to Nov. 27, Bristol-Myers said Wednesday.
Bristol-Myers Squibb Co (NYSE:BMY) The Leukemia & Lymphoma Society ...  Markets Wired
Market Movers: Starbucks Corporation (NASDAQ:SBUX), Bristol-Myers Squibb Co ...
L) and Bristol-Myers Squibb Company (BMY), declared that it has reached a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules that will be further developed to treat diseases such as ...
Buy The Dip On Bristol-Myers Squibb: J.P. Morgan
In a report published Tuesday, JP Morgan analyst Chris Schott maintained an Overweight rating on Bristol-Myers Squibb Co (NYSE: BMY), with a price target of $75.
Bristol-Myers Squibb Co. to close Wallingford facility, hundreds of jobs to be ...
WALLINGFORD - Bristol-Myers Squibb Co. will close its Research Parkway facility in early 2018, relocating up to 800 employees and eliminating about 100 jobs, the company announced Thursday.
Stock Report Bristol-Myers Squibb Co (NYSE:BMY)  Street Report
Bristol-Myers Squibb to open research site in Cambridge  Boston Globe
Stock to Follow: Bristol-Myers Squibb Co (NYSE:BMY)
[Business Wire] Bristol-Myers Squibb Co (NYSE:BMY)(TREND ANALYSIS) announced that the European Commission has approved Nivolumab BMS for the treatment of locally advanced or metastatic squamous (SQ) non-small cell lung cancer (NSCLC) after ...
Bristol-Myers Squibb's Nivolumab BMS receives EU approval to treat ...  pharmabiz.com
European Commission Approves Nivolumab BMS by Bristol-Myers Squibb for NSCLC  Lung Disease News
Bristol-Myers Squibb Becomes Oversold
But making Bristol-Myers Squibb Co. an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of BMY entered into oversold territory, changing hands as low as $51.82 per share.